Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $282.5 million.

  • Corcept Therapeutics' Non-Current Assets fell 1096.89% to $282.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 8030.56%. This contributed to the annual value of $369.0 million for FY2024, which is 12651.57% up from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' Non-Current Assets is $282.5 million, which was down 1096.89% from $358.6 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Non-Current Assets ranged from a high of $408.0 million in Q1 2025 and a low of $77.3 million during Q2 2022
  • Moreover, its 5-year median value for Non-Current Assets was $157.2 million (2021), whereas its average is $184.5 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first plummeted by 5593.82% in 2022, then surged by 16739.03% in 2025.
  • Corcept Therapeutics' Non-Current Assets (Quarter) stood at $157.3 million in 2021, then plummeted by 46.48% to $84.2 million in 2022, then skyrocketed by 93.5% to $162.9 million in 2023, then soared by 126.52% to $369.0 million in 2024, then fell by 23.44% to $282.5 million in 2025.
  • Its last three reported values are $282.5 million in Q3 2025, $358.6 million for Q2 2025, and $408.0 million during Q1 2025.